SCHEMBL3105207

SCHEMBL3105207

CCOC(=O)CC(=O)C=Cc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.62
RAB9A P51151 5/20 0.57
MAPT P10636 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55
APP P05067 1/20 0.54
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
KDM4E B2RXH2 1/20 0.53
KCNH2 Q12809 1/20 0.53
GSK3B P49841 2/20 0.51
NPC1 O15118 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 2/20 0.51
BACE1 P56817 1/20 0.51
EGFR P00533 2/20 0.50
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
GLA P06280 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3105202 1.00 HAO1 (0.62) HAO1RAB9AMAPTNPSR1APP
SCHEMBL11741671 0.91 HDAC2 (0.54) HAO1RAB9AMAPTNPSR1APP
SCHEMBL7423204 0.87 HAO1 (0.63) HAO1RAB9AMAPTNPSR1APP
SCHEMBL7423208 0.87 HAO1 (0.63) HAO1RAB9AMAPTNPSR1APP
SCHEMBL11547026 0.87 RAB9A (0.57) RAB9AMAPTALDH1A1KMT2AKDM4E
SCHEMBL6526696 0.86 HAO1 (0.66) HAO1RAB9AMAPTAPPALDH1A1
SCHEMBL10348533 0.86 HAO1 (0.66) HAO1RAB9AMAPTAPPALDH1A1
SCHEMBL12165488 0.86 HAO1 (0.57) HAO1RAB9AMAPTNPSR1APP
SCHEMBL7660175 0.86 ALDH1A1 (0.54) RAB9AMAPTNPSR1ALDH1A1MEN1
SCHEMBL5369201 0.85 ALDH1A1 (0.65) HAO1RAB9AMAPTNPSR1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101805312-A 4-alkyl-6-aryl-5-alkoxy acyl 1,3-thiazine and preparation method and application thereof UNIV HUNAN 2010-08-18 CN claimed
EP-0239105-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING 5-PHENYL-1,3-DIOXOALKENYL COMPOUNDS G.D. Searle & Co. (US) 1990-05-23 EP claimed
EP-0239105-A2 Pharmaceutical compositions containing 5-phenyl-1,3-dioxoalkenyl compounds G.D. Searle & Co. (US) 1987-09-30 EP claimed
US-8637674-B2 Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2014-01-28 US disclosed
US-20120232117-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2012-09-13 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
CN-101805312-A 4-alkyl-6-aryl-5-alkoxy acyl 1,3-thiazine and preparation method and application thereof UNIV HUNAN 2010-08-18 CN disclosed
EP-1481961-B1 PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE SUMITOMO CHEMICAL CO (JP) 2009-11-25 EP disclosed
CN-100528828-C Production method of racemiation3-hydroxy-3- (2-phenylethyl) hexanoic acid C1-6 alkyl ester SUMIKA FINE CHEMICALS CO LTD (JP) 2009-08-19 CN disclosed
EP-1894912-B1 Process for producing racemic 3-hydroxy-3-(2-phenylethyl) hexanoic acid ester SUMITOMO CHEMICAL CO (JP) 2009-08-05 EP disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-3981893-A HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DT) 1976-09-21 US disclosed
US-3974290-A Vasodilating and antihypertensive compositions and methods of effecting vasodilation and treating hypertension utilizing 2-amino-4H pyrane as the active agent BAYER AKTIENGESELLSCHAFT (DT) 1976-08-10 US disclosed
US-3971791-A VASODILATION, HYPOTENSIVE BAYER AKTIENGESELLSCHAFT (DT) 1976-07-27 US disclosed
US-3971790-A VASODILATION, HYPOTENSIVE BAYER AKTIENGESELLSCHAFT (DT) 1976-07-27 US disclosed
US-3966767-A CORONARY ACTION, ANTI-HYPERTENSIVE AGENTS BAYER AKTIENGESELLSCHAFT (DT) 1976-06-29 US disclosed
US-3959292-A HYPOTENSIVE AGENTS, CORONARY DILATORS BAYER AKTIENGESELLSCHAFT (DT) 1976-05-25 US disclosed
US-3946026-A HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS BAYER AKTIENGESELLSCHAFT (DT) 1976-03-23 US disclosed
US-3939171-A HYPOTENSIVE, VASODILATION BAYER AKTIENGESELLSCHAFT (DT) 1976-02-17 US disclosed
US-3935223-A 2-Amino-1,4-dihydropyridine derivatives BAYER AKTIENGESELLSCHAFT (DT) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 HAO1 406/4885RAB9A 2959/4885MAPT 4724/4885
US-20120232117-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME PTH1R, VDR, SOST HAO1 3880/4885RAB9A 1632/4885MAPT 3099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.